Features

Filter

Current filters:

None

Popular Filters

1 to 25 of 54 results

"My staff are involved in setting the global healthcare agenda:" interview with Parexel's Thomas Senderovitz

08-12-2014

With so many balls to juggle in the development pathway of a new drug, pharma companies looking for support…

InterviewsParexelParexelPharmaceuticalResearchThomas Senderovitz

Turning a constraint into an enabler: transparency round-table at Veeva's commercial summit 2014

Turning a constraint into an enabler: transparency round-table at Veeva's commercial summit 2014

05-12-2014

In one of the opening sessions, cloud-based life sciences provider Veeva’s co-founder and president…

BMI SystemEuropeInterviewsPharmaceuticalRegulationVeeva

The Global Crisis of Depression conference: high co-morbidity, high costs, few answers

The Global Crisis of Depression conference: high co-morbidity, high costs, few answers

27-11-2014

John Andrews, consultant editor of The Economist, opened the Global Crisis of Depression conference by…

InterviewsLundbeckNeurologicalPharmaceuticalResearchSocial IssuesUK

ESMO 2014: Eisai’s lenvatinib could revolutionize treatment of rare thyroid cancer

ESMO 2014: Eisai’s lenvatinib could revolutionize treatment of rare thyroid cancer

30-09-2014

An orphan drug could offer real hope to patients with rare thyroid cancer, Japanese drugmaker Eisai revealed…

EisaiInterviewsJapanlenvatinibOncologyPharmaceuticalResearch

EXPERT VIEW: Utilizing supplementary protection certificates for active ingredients in the pharma industry

EXPERT VIEW: Utilizing supplementary protection certificates for active ingredients in the pharma industry

29-09-2014

Intellectual Property can be vital for the success of any pharmaceutical invention. It is very important…

EuropeInterviewsLegalPatentsPharmaceuticalUnited Kingdom

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

EXPERT VIEW: The Interim Exec Community calls for a ‘Conscious Coupling’ of RPOs and Interims Specialists

EXPERT VIEW: The Interim Exec Community calls for a ‘Conscious Coupling’ of RPOs and Interims Specialists

19-09-2014

Pharmaceutical companies have widely adopted strategies to outsource elements of their business operations,…

BoardroomGlobalInterviewsPharmaceuticalRecruitment

EyeForPharma Multichannel Marketing Summit 2014: Lundbeck's Tim White on customer interaction, apps and buzzwords

EyeForPharma Multichannel Marketing Summit 2014: Lundbeck's Tim White on customer interaction, apps and buzzwords

19-09-2014

Tim White is head of global customer interaction at Lundbeck. The Pharma Letter spoke to him at the EyeForPharma…

DenmarkInterviewsLundbeckMarkets & MarketingNeurologicalPharmaceutical

EXPERT VIEW: Pfizer and AstraZeneca, a marriage not to be – yet?

EXPERT VIEW: Pfizer and AstraZeneca, a marriage not to be – yet?

19-08-2014

Mergers and acquisitions may excite the markets and shareholders on both sides but their record of success…

GlobalInterviewsMergers & AcquisitionsPharmaceutical

In Focus: The role of big data in the drug development process

In Focus: The role of big data in the drug development process

15-08-2014

As big data plays an increasing role in drug development and clinical trials, The Pharma Letter’s Bethany…

Clinical researchInterviewsMedidataPharmaceuticalPharmaceutical sciencesResearchRichard YoungTechnological tools

Executive Q&A: Thomas Hein, SVP commercial and regulatory affairs, Hermes Pharma

Executive Q&A: Thomas Hein, SVP commercial and regulatory affairs, Hermes Pharma

28-07-2014

In an interview with The Pharma Letter, Thomas Hein, senior vice president of commercial and regulatory…

Dosage formsDrug DeliveryGermanyHermes PharmaInterviewsPharmaceutical

Executive Q&A: Paul Higham, CEO of immatics

Executive Q&A: Paul Higham, CEO of immatics

27-05-2014

In an interview with The Pharma Letter, immatics chief executive Paul Higham discusses the company's…

BiotechnologyCancerGermanyHealth Medical Pharmaimmatics biotechnologiesImmunologyInterviewsMedicineOncologyVaccination

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

EGA Biosimilars: European monitoring and global business opportunities

EGA Biosimilars: European monitoring and global business opportunities

07-04-2014

The spotlight was on the European uptake of biosimilars at the European Generic medicines Association’s…

BiosimilarsEuropeGlobalInterviewsMarkets & Marketing

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

01-04-2014

The Pharma Letter interviewed chief executive Dr Thomas Taapken about Epigenomics’ lead product, increasing…

BiotechnologyEpi proColonEpigenomicsGermanyInterviewsOncology

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

20-03-2014

As health care budgets are squeezed worldwide and access issues continue to make the headlines, the price…

GlobalInterviewsPharmaceuticalPricing

1 to 25 of 54 results

Back to top